DOCSLIB.ORG

The Effects of Ouabain in Lambs with Depressed Myocardial Function

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effects of Ouabain in Lambs with Depressed Myocardial Function Pediatr. Res. 16: 357-361 (1982) The Effects of Ouabain in Lambs with Depressed Myocardial Function WILLIAM BERMAN, JR.,'"' STEVEN M. YABEK, AND RAMONA SHORTENCARRIER University of New Mexico, School of Medicine, Department of Pediatrics, Cardiology Division, Albuquerque, New Mexico, USA Summary mesh pouch, sewn to the skin. Animals were treated postopera- tively with 50,000 units/kg/day of penicillin and 15 mg/kg/day The effects of ouabain infusion were tested in six lambs before of Kanamycin, given intramuscularly. Studies were performed 48 and after depression of myocardial function by halothane anesthe- h or more after surgery. sia. Halothane reduced the left ventricular rate of pressure rise (dp/dt), stroke work, and stroke volume; the ratio of preejection RESTING STUDIES period to left ventricular ejection time rose. Heart rate and systemic vascular resistance did not change. Before halothane, Baseline measurements. Resting measurements of hemodynamic ouabain infusion did not alter the hemodynamic variables mea- function were made while the lambs rested quietly, blind- sured. After myocardial depression, ouabain infusion returned dp/ folded in an open cage. Physiologic data were recorded on a dt, stroke work, stroke volume and the ratio of preejection period Beckman R-611 direct writing recorder at paper speeds of 2.5, 10, to left ventricular ejection time to control levels. Pacing studies 25, 100 and 200 mm/sec. Arterial pH, Pcoz, Pop and hematocrit showed a biphasic relationship between left ventricular dp/dt and were measured on each study day. Aortic and right atrial pressures heart rate. Maximal dp/dt occurred at a heart rate 42 beats/min were recorded with Statham P23DB strain gauges. The ECG was higher than the resting rate. recorded with an AC/DC coupler (Beckman 9806-A). Left ven- These studies suggest resting myocardial performance in the tricular pressure was recorded with the Millar catheter and used healthy, newborn lamb is at near maximal level. to generate its first derivative with respect to time (LV dp/dt) with a Beckrnan 9879 differentiating circuit, calibrated both internally and by application of an external triangular waveform. Heart rate The tolerance to and physiologic effects of cardiac glycosides was recorded from the left ventricular signal with a cardiota- differ in newborn and adult sheep (1,2). Studies have shown that chometer (Beckman 9857). Systolic time intervals, preejection age-related variations in the pharmacokinetics, metabolism, pro- period (PEP) and left ventricular ejection time (LVET), were tein binding or tissue penetration of digoxin do not explain the measured using the ECG, aortic and left ventricular tracings, as biologic differences documented (3-7). The differences in drug described previously (8). Cardiac output was measured using effect may relate to developmental variation in the effects of indocyanine green dye and an Electronics for Medicine DCCO- cardiac glycosides on the myocardial sodium-potassium ATP-ase 044 densitometer/output computer with internal standardization. (Na-K ATP-ase) system. Recently, however, evidence has accu- Dye, 1.25mg. was injected into the right atrium; arterial blood was mulated that the resting level of myocardial function in healthy withdrawn sterilely at a rate of 38.2 ml/min for 20-30 sec to assure newborn lambs is much higher than that in mature sheep (8-10). linearity of the downslope of the curve. Four output determina- The high resting level of heart rate and myocardial function in tions were made on each study, the withdrawn blood reinfused the normal, nonfailing neonatal lamb heart may make inotropic after each determination and the results averaged. Systemic vas- stimulation with cardiac glycosides difficult to document. cular resistance and stroke work were calculated from the appro- We tested the effects of ouabain infusion on the hemodynamic priate measured variables. function of newborn lambs. Drug effects were measured in undis- Ouabain infusion. After baseline measurements had been made, turbed, chronically instrumented, awake animals; studies were lambs were given 50 &kg of ouabain, IV, and maintained on an repeated after myocardial depression by halothane anesthesia. We infusion of 0.05 pg/kg/min of ouabain for 45 min. The loading also studied the contribution of heart rate to resting myocardial and maintenance doses were modified from those used in adult function in newborn lambs by testing the effect of atrial pacing on dogs (1 I) in order to produce arrhythmias in the study animals. the hemodynamic variables measured. Subsequently, hemodynarnic measurements were repeated. MATERIALS AND METHODS HALOTHANE STUDY ANIMAL PREPARATION Twenty-four or more h after resting studies, measurements were made again while animals were udisturbed in the open cage. Studies were performed on six lambs ranging in age from 5-26 Thereafter, halothane anesthesia (0.5-1%) was administered via days and in weight from 3.8-12.5 kg. Animals were prepared face mask for 20 min before repeating hemodynamic rneasure- surgically using 0.5% halothane anesthesia, administered by face ments. Halothane anesthesia was continued during the adminis- mask, and pentobarbital sedation (5 mg/kg, IV). Polyvinyl cath- tration of ouabain by the same technique used previously. Mea- eters (0.050 inches ID; 0.090 inches OD) were inserted into the surements were then repeated before discontinuation of halothane right atrium via the jugular vein and into the descending abdom- anesthesia and ouabain infusion. inal aorta via the femoral artery. A #5 French Millar catheter tip manometer was positioned in heleft ventricle via the left carotid PACING STUDIES artery. Three electrocardiographic (ECG) electrodes'were sewn to the chest wall. Catheters, wires and the Millar transducer cable Twenty-four or more h after the halothane study, each of the were tunnelled subcutaneously to the left flank and encased in a six animals underwent tracheostomy and halothane anesthesia 358 BERMAN ET AL. Table 1. Baseline hemodynamic data Systemic Right Cardiac vascular re- Aortic atrial output sistance Hema- mean mean Heart rate dp/dt (ml- Stroke Stroke (mm Hg- Animal Age Weight tocrit Potassium Calcium pressure pressure (beats. (mm Hg. -PEP min-I- volume work (mm min. kg. (No.) (days) (kg) (%) (meq. L-I) (mg.dl-I) (mm Hg) (mm Hg) min-I) sec-') LVET kg-') (ml) Hg.ml) ml-I) I 8 5.2 28 3.9 9.1 80 I 170 3000 0.312 387 11.8 944 0.204 2 10 4 3 1 4.0 8.9 79 2 135 4000 0.257 375 11.1 877 0.205 3 11 6.8 30 4.2 9.5 85 5 220 4400 0.282 444 13.7 1164 0.180 4 5 4.5 29 4.4 9.0 84 3 190 5400 0.355 406 9.6 806 0.200 5 26 13 34 4.0 9.6 85 4 185 3200 0.310 279 18.6 1666 0.290 6 18 9 32 4.1 9.1 88 5 195 3000 0.322 325 15 1320 0.255 - x 13 7.1 31 4.1 9.2 84 3 182 3833 0.306 369 13.3 1130 0.222 S.D. 7.7 3.4 2 0.2 0.3 3 2 28 958 0.034 59 3.2 325 0.041 Table 2. Change in hemodynamic variables relative to baseline were less than 2 wk old. The variation in heart rate, dp/dt, stroke measurements after ex~erimentalintervention volume and stroke work between animals was moderate; values Quabain infu- Halothane anes- Halothane and for mean aortic and right atrial pressure, PEP/LVET, cardiac sion thesia ouabain output per kg and systemic vascular resistance were more consist- ent. dp/dt (mm Hg.sec-I) 3975 (3.8)' 2758 (-27.21~ 3817 (0.4) The effects of experimental intervention on six variables reflec- Stroke volume (ml) 14.2 (5.4) 10.0(-25.6)2 13.6(1.0) tive of myocardial function are shown in Table 2. Because of the Stroke work (mm Hg. 1181 (5.4) 766 (-30. I)~ 1082 (-3.3) moderate variation in baseline values of dp/dt, stroke volume and ml) stroke work between animals, changes after intervention were PEP/LVET 0.280(-8.5) 0.41 1 (34.3)2 0.294(-3.9) examined by a two way analysis of variance. Heart rate (beats. min-I) 174(-4.4) 186 (1.6) I85 (1.6) Ouabain infusion caused no significant change in left ventric- Systemic vascular resist- 0.227 (3.3) 0.238 (7.5) 0.224 (0.9) ular dp/dt, stroke volume, stroke work, heart rate, systemic vas- ance (mm Hg.min. cular resistance or the PEP/LVET ratio from baseline values. kg. ml-I) Although 5 of 6 animals showed some arrhythmia during drug I Mean absolute value (mean % change from control). infusion (ventricular premature contractions in 3, junctional pre- Differs from control, by analysis of variance, P < 0.01. mature contractions in 2), physiologic measurements were made during periods of stable sinus rhythm. Hemodynamic data measured prior to halothane anesthesia did before right thoracotomy. Resting measurements were made be- not differ from measurements defined as baseline. Halothane fore further manipulation. Next, pacing electrodes were sewn to anesthesia depressed myocardial function, as evidenced by sig- the superior vena cava-right atrial junction and the right atrial nificant reductions in left ventricular dp/dt, stroke volume and lateral wall. The sinus node region was crushed with a hemostat stroke work, and caused a significant elevation in the PEP/LVET to lower resting heart rate. The pacing electrodes were connected ratio. Halothane anesthesia caused no consistent change in heart to a modified, electrically isolated pulse generator (Grass SD9) so rate or systemic vascular resistance, as reported previously (14, that impulses of varying rate, 2 msec in duration, and 2-7 mA in 15).
Load more

Recommended publications
  • Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis Lanata Leaves
    Pharmacology & Pharmacy, 2016, 7, 200-207 Published Online May 2016 in SciRes. http://www.scirp.org/journal/pp http://dx.doi.org/10.4236/pp.2016.75026 Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis lanata Leaves Yasuhiko Higashi*, Yukari Ikeda, Youichi Fujii Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan Received 21 April 2016; accepted 28 May 2016; published 31 May 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract We previously developed an HPLC method for determination of lanatoside C, digoxin and α-acetyl- digoxin in digitalis glycosides isolated from Digitalis lanata leaves. Here, we present an improved HPLC-UV method to determine those compounds and deslanoside. We used the improved method to examine the effects of various pretreatments on the amounts of the four compounds isolated from the leaves, with the aim of maximizing the yield of digoxin. Leaves were extracted with 50% methanol, followed by clean-up on a Sep-Pak C18 cartridge prior to HPLC analysis. The amounts of lanatoside C, digoxin and α-acetyldigoxin per 100 mg of the leaves without pretreatment were 115.6, 7.45 and 23.8 μg, respectively (deslanoside was not detected). Pretreatment with acetic ac- id, which activated deglucosylation mediated by digilanidase present in the leaves, increased the amounts of digoxin and α-acetyldigoxin, while lanatoside C and deslanoside were not detected. Pretreatment with sodium methoxide, which hydrolyzed lanatoside C to deslanoside, increased the yields of deslanoside and digoxin, while lanatoside C and α-acetyldigoxin were not detected.
    [Show full text]
  • Pharmacokinetics, Bioavailability and Serum Levels of Cardiac Glycosides
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE JACCVol. 5, No.5 provided by Elsevier - Publisher43A Connector May 1985:43A-50A Pharmacokinetics, Bioavailability and Serum Levels of Cardiac Glycosides THOMAS W. SMITH, MD, FACC Boston. Massachusetts Digoxin, the cardiac glycoside most frequently used in bioavailability of digoxin is appreciably less than that of clinical practice in the United States, can be givenorally digitoxin, averaging about two-thirds to three-fourths of or intravenously and has an excretory half-life of 36 to the equivalent dose given intravenously in the case of 48 hours in patients with serum creatinine and blood currently available tablet formulations. Recent studies urea nitrogen values in the normal range. Sincethe drug have shown that gut ftora of about 10% of patients re­ is excreted predominantly by the kidney, the half-life is duce digoxin to a less bioactive dihydro derivative. This prolonged progressivelywithdiminishingrenal function, process is sensitiveto antibiotic administration, creating reaching about 5 days on average in patients who are the potential for important interactions among drugs. essentially anephric. Serum protein binding of digoxin Serum or plasma concentrations of digitalis glycosides is only about 20%, and differs markedly in this regard can be measured by radioimmunoassay methods that are from that of digitoxin, which is 97% bound by serum nowwidelyavailable, but knowledgeofserum levelsdoes albumin at usual therapeutic levels. Digitoxin is nearly not substitute for a sound working knowledge of the completely absorbed from the normal gastrointestinal clinical pharmacology of the preparation used and care­ tract and has a half-lifeaveraging 5 to 6 days in patients ful patient follow-up.
    [Show full text]
  • Protective Effect of Eicosapentaenoic Acid on Ouabain Toxicity in Neonatal
    Proc. Nati. Acad. Sci. USA Vol. 87, pp. 7834-7838, October 1990 Medical Sciences Protective effect of eicosapentaenoic acid on ouabain toxicity in neonatal rat cardiac myocytes (cardiac glycoside toxicity/w-3 fatty acid effect/cytosolic calcium overload/cardiac antiarrhythmic/Na,K-ATPase inhibition) HAIFA HALLAQ*t, ALOIS SELLMAYERt, THOMAS W. SMITH§, AND ALEXANDER LEAF* *Department of Preventive Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114; tInstitut fur Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Universitat Munchen, Pettenkofer Strasse 9, 8000 Munich 2, Federal Republic of Germany; and §Cardiovascular Division, Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02114 Contributed by Alexander Leaf, June 26, 1990 ABSTRACT Isolated neonatal cardiac myocytes have been sarcolemmal membranes of the heart cells. Furthermore, a utilized as a model for the study of cardiac arrhythmogenic prospective randomized clinical trial (7) showed that, among factors. The myocytes respond to the toxic effects of a potent men who had recently suffered a myocardial infarction, those cardiac glycoside, ouabain at 0.1 mM, by an increase in their that were advised to eat fish two or three times a week had spontaneous beating rate and a reduction in amplitude of a 29% reduction in fatal myocardial infarctions over a sub- contractions resulting within minutes in a lethal state of sequent 2-year period compared to those patients not given contracture. Incubating the isolated myocytes for 3-S5 days in such advice. There was, however, no significant difference in culture medium enriched with 5 ,IM arachidonic acid [20:4 cardiac events; those eating fish just did not die as frequently (n-6)] had no effect on the development of lethal contracture of their myocardial infarctions.
    [Show full text]
  • Multidose Evaluation of 6,710 Drug Repurposing Library Identifies Potent SARS-Cov-2 Infection Inhibitors in Vitro and in Vivo
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.20.440626; this version posted April 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Multidose evaluation of 6,710 drug repurposing library identifies potent SARS-CoV-2 infection inhibitors In Vitro and In Vivo. JJ Patten1, P. T. Keiser 1, D. Gysi2,3, G. Menichetti 2,3, H. Mori 1, C. J. Donahue 1, X. Gan 2,3, I. Do Valle 2, , K. Geoghegan-Barek 1, M. Anantpadma 1,4, J. L. Berrigan 1, S. Jalloh1, T. Ayazika1, F. Wagner6, M. Zitnik 2, S. Ayehunie6, D. Anderson1, J. Loscalzo3, S. Gummuluru1, M. N. Namchuk7, A. L. Barabasi2,3,8, and R. A. Davey1. Addresses: 1. Department of Microbiology, Boston University School of Medicine and NEIDL, Boston University, Boston, MA, 02118, USA. 2. Center for Complex Network Research, Northeastern University, Boston, Massachusetts 02115, USA. 3. Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. 4. present address: Analytical Development, WuXi Advanced Therapies, Philadelphia, PA, 19112, USA. 5. Center for the Development of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA. 6. MatTek Corporation, Ashland, MA 01721, USA. 7. Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA. 02115, USA. 8. Department of Network and Data Science, Central European University, Budapest 1051, Hungary. Abstract The SARS-CoV-2 pandemic has caused widespread illness, loss of life, and socioeconomic disruption that is unlikely to resolve until vaccines are widely adopted, and effective therapeutic treatments become established.
    [Show full text]
  • Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/Mtor Signaling Pathways
    biomolecules Article Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways Dhanasekhar Reddy 1 , Ranjith Kumavath 1,* , Preetam Ghosh 2 and Debmalya Barh 3 1 Department of Genomic Science, School of Biological Sciences, Central University of Kerala, Tejaswini Hills, Periya (P.O) Kasaragod 671316, Kerala, India; [email protected] 2 Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA; [email protected] 3 Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur 721172, West Bengal, India; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +91-8547-648-620 Received: 21 October 2019; Accepted: 22 November 2019; Published: 27 November 2019 Abstract: Cardiac glycosides (CGs) are a diverse family of naturally derived compounds having a steroid and glycone moiety in their structures. CG molecules inhibit the α-subunit of ubiquitous transmembrane protein Na+/K+-ATPase and are clinically approved for the treatment of cardiovascular diseases. Recently, the CGs were found to exhibit selective cytotoxic effects against cancer cells, raising interest in their use as anti-cancer molecules. In this current study, we explored the underlying mechanism responsible for the anti-cancer activity of Lanatoside C against breast (MCF-7), lung (A549), and liver (HepG2) cancer cell lines. Using
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0246185 A1 Kishida Et Al
    US 20090246185A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0246185 A1 Kishida et al. (43) Pub. Date: Oct. 1, 2009 (54) CARDIAC DYSFUNCTION-AMELIORATING (30) Foreign Application Priority Data AGENT OR CARDAC FUNCTION-MANTAININGAGENT Mar. 13, 2006 (JP) ................................. 2006-066992 Nov. 21, 2006 (JP) ................................. 2006-314034 (75) Inventors: Hideyuki Kishida, Hyogo (JP); O O Kenji Fujii, Hyogo (JP); Hiroshi Publication Classification Kubo, Hyogo (JP); Kazunori (51) Int. Cl. Hosoe, Hyogo (JP) A6II 3L/22 (2006.01) CD7C 43/23 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) SUGHRUE MION, PLLC (52) U.S. Cl. ........................................ 424/94.1:568/651 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (57) ABSTRACT WASHINGTON, DC 20037 (US) An object of the present invention is to provide a highly safe oral composition Superior in a cardiac dysfunction-amelio (73) Assignee: KANEKA CORPORATION, rating or cardiac function-maintaining action. The present OSAKA-SHI, OSAKA (JP) inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that use of (21) Appl. No.: 12/282,448 particularly, reduced coenzyme Q10 from among highly safe coenzyme Q affords a composition useful for amelioration of (22) PCT Filed: Mar. 9, 2007 cardiac dysfunction and maintenance of cardiac function. Accordingly, the present invention provides a cardiac dys (86). PCT No.: PCT/UP2007/O54.643 function-ameliorating agent or cardiac function-maintaining agent containing reduced coenzyme Qas an active ingredient, S371 (c)(1), and a pharmaceutical product, a food, an animal drug, a feed (2), (4) Date: Dec. 23, 2008 and the like, which contain the agent.
    [Show full text]
  • Eiichi Kimura, MD, Department of Internal Medicine, Nippon Medical
    Effect of Metildigoxin (ƒÀ-Methyldigoxin) on Congestive Heart Failure as Evaluated by Multiclinical Double Blind Study Eiichi Kimura,* M.D. and Akira SAKUMA,** Ph.D. In Collaboration with Mitsuo Miyahara, M.D. (Sapporo Medi- cal School, Sapporo), Tomohiro Kanazawa, M.D. (Akita Uni- versity School of Medicine, Akita), Masato Hayashi, M.D. (Hiraga General Hospital, Akita), Hirokazu Niitani, M.D. (Showa Uni- versity School of Medicine, Tokyo), Yoshitsugu Nohara, M.D. (Tokyo Medical College, Tokyo), Satoru Murao, M.D. (Faculty of Medicine, University of Tokyo, Tokyo), Kiyoshi Seki, M.D. (Toho University School of Medicine, Tokyo), Michita Kishimoto, M.D. (National Medical Center Hospital, Tokyo), Tsuneaki Sugi- moto, M.D. (Faculty of Medicine, Kanazawa University, Kana- zawa), Masao Takayasu, M.D. (National Kyoto Hospital, Kyoto), Hiroshi Saimyoji, M.D. (Faculty of Medicine, Kyoto University, Kyoto), Yasuharu Nimura, M.D. (Medical School, Osaka Uni- versity, Osaka), Tatsuya Tomomatsu, M.D. (Kobe University, School of Medicine, Kobe), and Junichi Mise, M.D. (Yamaguchi University, School of Medicine, Ube). SUMMARY The efficacy on congestive heart failure of metildigoxin (ƒÀ-methyl- digoxin, MD), a derivative of digoxin (DX), which had a good absorp- tion rate from digestive tract, was examined in a double blind study using a group comparison method. After achieving digitalization with oral MD or intravenous deslanoside in the non-blind manner, mainte- nance treatment was initiated and the effects of orally administered MD and DX were compared. MD was administered in 44 cases , DX in 42. The usefulness of the drug was evaluated after 2 weeks , taking into account the condition of the patient and the ease of administration .
    [Show full text]
  • Radioimmunoassay
    Radioimmunoassay Measurement of Serum Cardiac Glycoside Levels: Using Pharmacologic Principles to Solve Crossreactivity Problems Thomas J. Persoon The University of Iowa, Iowa City, Iowa Laboratories performing analyses for serum cardiac Results glycosides are sometimes faced with the problem of dis­ Data collected in our laboratory are similar to those tinguishing between digoxin and digitoxin in a specimen. published by Kuno-Sakai. Tables 3 and 4 show the The antibodies to the cardiac glycosides supplied with measured concentrations of digoxin and digitoxin from radioimmunoassay kits for these drugs have some patient sera known to contain only one drug. Figure 1 measurable degree of cross reactivity. Therapeutic levels is a plot of measured digoxin levels versus actual of digitoxin are approximately ten times greater than digitoxin concentration of serum digitoxin standards. those of digoxin, and the half-lives of these drugs in The slope and intercept of the line were determined by serum differ by a factor of four. These facts have been the linear least-squares technique. combined into a series of rules which allow the technologist to distinguish between digoxin and digitoxin Discussion in a sample and provide a level of the drug that has been corrected for crossreactivity. Figure 2 shows the chemical structures of four cardiac glycosides: digoxin, digitoxin, cedilanid, and In 1972 Edmonds et al. ( 1) published data on the crossreactivity of digitoxin in the digoxin radioim­ TABLE 1. Crossreactivity of Digitoxin in Digoxin RIA munoassay (Tables 1 and 2). They showed the slopes Measured level of of digoxin-digitoxin cross reactivity plots to be linear. Digitoxin added (ng/mll digoxin (ng/mll Kuno-Sakai et al.
    [Show full text]
  • Quo Vadis Cardiac Glycoside Research?
    toxins Review Quo vadis Cardiac Glycoside Research? Jiˇrí Bejˇcek 1, Michal Jurášek 2 , VojtˇechSpiwok 1 and Silvie Rimpelová 1,* 1 Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, Prague 6, Czech Republic; [email protected] (J.B.); [email protected] (V.S.) 2 Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 3, Prague 6, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +420-220-444-360 Abstract: AbstractCardiac glycosides (CGs), toxins well-known for numerous human and cattle poisoning, are natural compounds, the biosynthesis of which occurs in various plants and animals as a self-protective mechanism to prevent grazing and predation. Interestingly, some insect species can take advantage of the CG’s toxicity and by absorbing them, they are also protected from predation. The mechanism of action of CG’s toxicity is inhibition of Na+/K+-ATPase (the sodium-potassium pump, NKA), which disrupts the ionic homeostasis leading to elevated Ca2+ concentration resulting in cell death. Thus, NKA serves as a molecular target for CGs (although it is not the only one) and even though CGs are toxic for humans and some animals, they can also be used as remedies for various diseases, such as cardiovascular ones, and possibly cancer. Although the anticancer mechanism of CGs has not been fully elucidated, yet, it is thought to be connected with the second role of NKA being a receptor that can induce several cell signaling cascades and even serve as a growth factor and, thus, inhibit cancer cell proliferation at low nontoxic concentrations.
    [Show full text]
  • Studies on Myocardial Metabolism. V. the Effects of Lanatoside-C on the Metabolism of the Human Heart
    STUDIES ON MYOCARDIAL METABOLISM. V. THE EFFECTS OF LANATOSIDE-C ON THE METABOLISM OF THE HUMAN HEART J. M. Blain, … , A. Siegel, R. J. Bing J Clin Invest. 1956;35(3):314-321. https://doi.org/10.1172/JCI103280. Research Article Find the latest version: https://jci.me/103280/pdf STUDIES ON MYOCARDIAL METABOLISM. V. THE EFFECTS OF LANATOSIDE-C ON THE METABOLISM OF THE HUMAN HEART 1 By J. M. BLAIN, E. E. EDDLEMAN, A. SIEGEL, AND R. J. BING (From the Departments of Experimental Medicine and Clinical Physiology, The Medical College of Alabama, Birmingham, Alabama, and the Veterans' Administration Hospital, Birmingham, Ala.) (Submitted for publication Septenber 6, 1955; accepted November 16, 1955) Since 1785 when Withering undertook the first this method should aid in elucidating the meta- systemic study of the effects of digitalis, a large bolic pathways within the heart muscle; thus reac- amount of data has been accumulated describing tions determined by more precise in vitro methods its pharmacological effects. Despite intensive could be re-evaluated in the light of data obtained study, the underlying mechanism responsible for on the human heart in vivo. the beneficial results in patients with heart failure The various cardiac glycosides differ in time of remains obscure. Although digitalis in small doses onset and persistence of action. Lanatoside-C, the may affect the heart rate through its vagal effect, preparation used in this study, is a purified deriva- it is agreed that the predominant action of this tive of digitalis lanata which can be given intra- drug is on the heart muscle directly (1).
    [Show full text]
  • Oleandrin: a Cardiac Glycosides with Potent Cytotoxicity
    PHCOG REV. REVIEW ARTICLE Oleandrin: A cardiac glycosides with potent cytotoxicity Arvind Kumar, Tanmoy De, Amrita Mishra, Arun K. Mishra Department of Pharmaceutical Chemistry, Central Facility of Instrumentation, School of Pharmaceutical Sciences, IFTM University, Lodhipur, Rajput, Moradabad, Uttar Pradesh, India Submitted: 19-05-2013 Revised: 29-05-2013 Published: **-**-**** ABSTRACT Cardiac glycosides are used in the treatment of congestive heart failure and arrhythmia. Current trend shows use of some cardiac glycosides in the treatment of proliferative diseases, which includes cancer. Nerium oleander L. is an important Chinese folk medicine having well proven cardio protective and cytotoxic effect. Oleandrin (a toxic cardiac glycoside of N. oleander L.) inhibits the activity of nuclear factor kappa‑light‑chain‑enhancer of activated B chain (NF‑κB) in various cultured cell lines (U937, CaOV3, human epithelial cells and T cells) as well as it induces programmed cell death in PC3 cell line culture. The mechanism of action includes improved cellular export of fibroblast growth factor‑2, induction of apoptosis through Fas gene expression in tumor cells, formation of superoxide radicals that cause tumor cell injury through mitochondrial disruption, inhibition of interleukin‑8 that mediates tumorigenesis and induction of tumor cell autophagy. The present review focuses the applicability of oleandrin in cancer treatment and concerned future perspective in the area. Key words: Cardiac glycosides, cytotoxicity, oleandrin INTRODUCTION the toad genus Bufo that contains bufadienolide glycosides, the suffix-adien‑that refers to the two double bonds in the Cardiac glycosides are used in the treatment of congestive lactone ring and the ending-olide that denotes the lactone heart failure (CHF) and cardiac arrhythmia.
    [Show full text]